DelveInsight’s ‘HER2 Negative Breast Cancer Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline HER2 Negative Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the HER2 Negative Breast Cancer pipeline domain.
For HER2 Negative Breast Cancer emerging drugs, the HER2 Negative Breast Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the HER2 Negative Breast Cancer Pipeline Report
- DelveInsight’s HER2 Negative Breast Cancer Pipeline analysis depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2 Negative Breast Cancer treatment.
- The leading HER2 Negative Breast Cancer companies include BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and others are evaluating their lead assets to improve the HER2 Negative Breast Cancer treatment landscape.
- Key HER2 Negative Breast Cancer pipeline therapies in various stages of development include BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others.
- In January 2023, Context Therapeutics Inc., a company developing novel treatments for solid tumors with a primary focus on female cancers, announced that its clinical trial collaborator, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), received FDA approval for ORSERDU (elacestrant) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- On January 27, 2023, the FDA approved elacestrant (Orserdu) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who had disease progression after at least one line of endocrine therapy.
- In January 2023, Daiichi Sankyo and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy indicated for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
- In January 2023, Gilead Sciences, Inc. announced that the European Medicines Agency (EMA) had validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Request a sample and discover the recent breakthroughs happening in the HER2 Negative Breast Cancer pipeline landscape @ HER2 Negative Breast Cancer Pipeline Outlook
HER2 Negative Breast Cancer Overview
The majority of breast cancers express the estrogen receptor (ER) and are negative for the human epidermal growth factor receptor 2 (HER2). ER+/HER2 -ve Breast Cancer refers to tumors that are ER-positive and PR-positive but HER2-negative. ER+/HER2 – positive breast cancer is diverse and accounts for approximately 70% of all breast cancers. HER2 is an abbreviation for human epidermal growth factor receptor 2. Some types of breast cancer have hormone receptors such as estrogen or progesterone (or both) and are referred to as ER+ or PR+ breast cancer.
Find out more about HER2 Negative Breast Cancer medication @ New Drugs for HER2 Negative Breast Cancer
HER2 Negative Breast Cancer Pipeline Analysis: Drug Profile
Capivasertib + Fulvestrant: AstraZeneca
Capivasertib (AZD5363) is a highly selective oral inhibitor of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently being studied in phase III clinical trials for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer who have recurred or progressed on or after aromatase inhibitor (AI) therapy.
Dalpiciclib: Jiangsu HengRui Medicine
Dalpiciclib (SHR 6390) is an orally administered small molecule that inhibits cyclin-dependent kinase (CDK)-4/6. Dalpiciclib is being tested in Phase III clinical trials with Letrozole, Anastrozole, or Fulvestrant in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.
HER2 Negative Breast Cancer Pipeline Therapies and Key Companies
- BGB-290: BeiGene
- OP-1250: Olema Pharmaceuticals, Inc.
- AZD9833: AstraZeneca
- ADG106: Adagene Inc
- Dato-DXd: Daiichi Sankyo, Inc.
- HRS8807: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Ipatasertib: Genentech
- CX-2009: CytomX Therapeutics
- BPI-1178: Beta Pharma (Suzhou) Co., Ltd.
Learn more about the novel and emerging HER2 Negative Breast Cancer pipeline therapies @ HER2 Negative Breast Cancer Clinical Trials
HER2 Negative Breast Cancer Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Intravenous
- Inhalation
- Subcutaneous
- By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
Scope of the HER2 Negative Breast Cancer Pipeline Report
- Coverage: Global
- Key HER2 Negative Breast Cancer Companies: BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and others.
- Key HER2 Negative Breast Cancer Pipeline Therapies: BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others.
Dive deep into rich insights for drugs used for HER2 Negative Breast Cancer treatment; visit @ HER2 Negative Breast Cancer Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | HER2 Negative Breast Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | HER2 Negative Breast Cancer Pipeline Therapeutics |
| 6. | HER2 Negative Breast Cancer Pipeline: Late Stage Products (Phase III) |
| 7. | HER2 Negative Breast Cancer Pipeline: Late Stage Products (Phase III) |
| 8. | HER2 Negative Breast Cancer Pipeline: Mid Stage Products (Phase II) |
| 9. | HER2 Negative Breast Cancer Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the HER2 Negative Breast Cancer therapy in the pipeline, reach out @ HER2 Negative Breast Cancer Medication
Related Reports
HER2-Positive Breast Cancer Market
HER2-Positive Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive breast cancer companies, including Shanghai Henlius Biotech, Roche Pharma AG, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, among others.
HER2-Positive Breast Cancer Epidemiology
HER2-Positive Breast Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted HER2-positive breast cancer epidemiology in the 7MM.
HER2-Positive Early Breast Cancer Pipeline
HER2-Positive Early Breast Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
HER2-Positive Early Breast Cancer Market
HER2-Positive Early Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
HER2-Negative Breast Cancer Market
HER2-Negative Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-negative breast cancer companies, including Sanofi, BeiGene, AstraZeneca, Radius Pharmaceuticals, Novartis, Amgen, among others.
Other Trending Reports
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
Related Cases Studies
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187